Lantheus Holdings (LNTH) Accumulated Expenses (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Accumulated Expenses came in at $286.5 million in Q1 2026, up 41.56% year-on-year from $202.4 million in Q1 2025, and up 7.18% on a QoQ basis from $267.3 million in Q4 2025.
Lantheus Holdings (LNTH) Accumulated Expenses (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Accumulated Expenses data on file, last reported at $286.5 million in Q1 2026.
- On a quarterly basis, Accumulated Expenses rose 41.56% year-over-year to $286.5 million in Q1 2026; TTM through Mar 2026 was $286.5 million, a 41.56% increase from a year earlier, with the FY2025 full-year figure at $267.3 million, up 453.85% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $286.5 million, up from $267.3 million in the prior quarter.
- Over the last five years, Accumulated Expenses for LNTH reached as high as $286.5 million in Q1 2026 and fell as low as $48.3 million in Q4 2024.
- Historically, Accumulated Expenses has averaged $178.7 million across 5 years, with a median of $183.8 million in 2022.
- Across the five-year window, Accumulated Expenses plunged 66.79% in 2024 and jumped 453.85% in 2025, its largest moves.
- Year by year, Accumulated Expenses stood at $127.1 million in 2022, then rose by 14.36% to $145.3 million in 2023, then slumped by 66.79% to $48.3 million in 2024, then soared by 453.85% to $267.3 million in 2025, then grew by 7.18% to $286.5 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $286.5 million in Q1 2026, $267.3 million in Q4 2025, and $251.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 286.49 Mn |
| Dec 31, 2025 | 267.31 Mn |
| Sep 30, 2025 | 251.11 Mn |
| Jun 30, 2025 | 208.60 Mn |
| Mar 31, 2025 | 202.38 Mn |
| Dec 31, 2024 | 48.26 Mn |
| Sep 30, 2024 | 174.45 Mn |
| Jun 30, 2024 | 212.64 Mn |
| Mar 31, 2024 | 198.94 Mn |
| Dec 31, 2023 | 145.34 Mn |
| Sep 30, 2023 | 138.82 Mn |
| Jun 30, 2023 | 114.80 Mn |
| Mar 31, 2023 | 145.47 Mn |
| Dec 31, 2022 | 127.08 Mn |
| Sep 30, 2022 | 190.48 Mn |
| Jun 30, 2022 | 183.80 Mn |
| Mar 31, 2022 | 142.40 Mn |
| Dec 31, 2021 | 58.07 Mn |
| Sep 30, 2021 | 46.04 Mn |
| Jun 30, 2021 | 41.98 Mn |